Skip to main content

Table 1 Clinicopathological characteristics of patients in the training, internal validation and external validation cohorts (N(%))

From: Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study

Characteristics

SEER

SEER

HUST-JU

Training cohort

P

Internal validation cohort

P

External validation cohort

P

Alive

Dead

 

Alive

Dead

 

Alive

Dead

 

N = 163

N = 668

N = 55

N = 301

N = 21

N = 42

Age

 < 60

88(53.98)

265(39.67)

0.001

31(56.36)

111(36.88)

0.007

14(66.67)

8(19.05)

< 0.001

 ≥60

75(46.02)

403(60.33)

 

24(43.64)

190(63.12)

 

7(33.33)

34(80.95)

 

Sex

 Male

84(51.53)

358(53.69)

0.637

25(45.45)

165(54.82)

0.202

11(52.38)

23(54.76)

0.861

 Female

79(48.47)

310(46.41)

 

30(54.55)

136(45.18)

 

10(47.62)

19(45.24)

 

Tumor location

 Colon

111(71.78)

544(81.44)

0.001

44(80.00)

250(83.06)

0.584

12(57.14)

39(92.86)

< 0.001

 Rectum

52(28.22)

124(18.56)

 

11(20.00)

51(16.94)

 

9(42.86)

3(7.14)

 

Differentiation

 Well

7(4.29)

24(3.59)

0.160

2(3.63)

13(4.32)

0.162

4(19.05)

1(2.38)

0.245

 Moderately

123(75.46)

444(66.47)

 

44(80.00)

210(69.77)

 

13(61.90)

29(69.05)

 

 Poorly

22(13.50)

147(22.01)

7(12.73)

56(18.60)

3(14.29)

10(23.36)

 Undifferentiated

3(1.85)

35(5.24)

2(3.64)

17(5.65)

0(0)

1(2.38)

 Unknow

8(4.90)

18(2.69)

0(0)

5(1.66)

1(4.76)

1(2.38)

Histological type

 Adenocarcinoma

147(90.18)

579(86.68)

0.619

51(92.73)

261(86.72)

0.694

19(90.48)

37(88.10)

0.574

 Mucinous adenocarcinoma

6(3.68)

48(7.19)

 

0(0)

20(6.64)

 

1(4.76)

5(11.90)

 

 Signet ring cell carcinoma

0(0)

2(0.30)

0(0)

1(0.33)

0(0)

0(0)

 Other

10(6.14)

39(5.83)

4(7.27)

19(12.31)

1(4.76)

0(0)

Size, mm

 <  55

100(61.35)

328(49.10)

0.005

35(63.64)

161(53.49)

0.165

17(80.95)

25(59.52)

0.072

 ≥ 55

63(38.65)

340(50.90)

 

20(36.36)

140(46.51)

 

4(19.05)

17(40.48)

 

TNM stage

 IVB

163(100)

668(100)

 

55(100)

301(100)

 

21(100)

42(100)

 T1

2(1.23)

3(0.45)

0(0)

0(0)

0(0)

0(0)

0.075

T stage

 T2

6(3.68)

13(1.95)

 

0(0)

4(1.33)

 

0(0)

0(0)

 

 T3

108(66.26)

352(52.69)

34(61.82)

152(50.50)

15(68.12)

20(47.62)

 T4

47(28.83)

300(44.91)

21(38.18)

145(48.17)

6(31.88)

22(52.38)

 N0

32(19.63)

78(11.68)

< 0.001

7(12.73)

26(8.64)

0.029

3(14.29)

2(4.76)

0.001

N stage

 N1

78(47.85)

233(34.88)

 

27(49.09)

109(36.21)

 

4(19.05)

5(11.90)

 

 N2

53(32.52)

357(53.44)

21(38.18)

166(55.15)

14(66.66)

35(83.34)

M stage

 M1a

0(0)

0(0)

–

0(0)

0(0)

–

0(0)

0(0)

–

 M1b

163(100)

668(100)

1

55(100)

301(100)

1

21(100)

42(100)

1

Radiotherapy

 Yes

29(17.79)

31(4.64)

< 0.001

2(3.64)

9(2.99)

0.800

4(19.05)

2(4.76)

0.071

 None/Unknown

143(82.21)

637(95.36)

 

53(96.36)

292(97.01)

 

17(80.95)

40(95.24)

 

Chemotherapy

 Yes

150(92.02)

446(66.77)

< 0.001

48(87.27)

194(64.45)

0.001

17(80.95)

24(57.14)

0.047

 None/Unknown

13(7.98)

222(33.23)

 

7(12.73)

107(35.55)

 

4(19.05)

18(42.86)

 

No. of sampled LNs Median (IR)

16(11)

16(10)

0.219

16(10)

16(10)

0.821

20(9)

16(9)

0.031

No. of Positive LNs Median (IR)

2(5)

4(7)

< 0.001

4(5)

3(7)

0.001

2(5)

2(7)

0.570

Primary surgery

 Yes

163(100)

667(99.85)

0.622

53(100)

300(99.67)

0.670

21(100)

41(97.62)

0.484

 No

0

1(0.15)

 

0

1(0.33)

 

0(0)

1(2.38)

 

Metastatic surgery

 Yes

49(30.06)

118(17.66)

< 0.0001

11(20.00)

59(19.60)

0.946

5(23.81)

4(9.52)

0.131

 No

114(69.94)

550(82.34)

 

44(80.80)

242(80.40)

 

16(76.19)

38(90.48)

 

CSS

 Yes

91

491

0.211

25

217

0.236

11

37

0.025

 No

72

177

 

30

84

 

10

4

Â